RxDoctor Payments Data

Lisa Nazarenus

Nurse Practitioner · Portland, TNNPI 1225200306

Payments from drug & device makers

$7,729in general payments, 2019–2025

Across 485 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$941
  • Lilly USA, LLC$535
  • Pfizer$375
  • GSK$364
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$7,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,729 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,741
Medicare patients
140
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$52,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$48,645
EliquisApixaban42$32,121
MounjaroTirzepatide15$29,855
JardianceEmpagliflozin21$23,410
Tresiba Flextouch U-200Insulin Degludec24$19,070
Synjardy XrEmpagliflozin/Metformin Hcl16$11,445
Combivent RespimatIpratropium/Albuterol Sulfate13$6,104
Raloxifene Hcl62$3,633
SynthroidLevothyroxine Sodium79$3,444
Fluticasone Propionate77$2,472
Celecoxib31$2,445
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen85$2,223
Rosuvastatin Calcium160$2,223
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21$2,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,397$52,19541 claims
GSKTrelegy Ellipta$364$48,64550 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$102$40,95950 claims
PfizerEliquis$375$32,12142 claims
Lilly USA, LLCMounjaro$535$29,85515 claims
AbbVieSynthroid$1,634$3,44479 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Portland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →